Videos

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell lung cancer, prompting further research.

An expert discusses emerging frontline treatments for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting the evolving role of regimens like FLORA2 and MARIPOSA, and emphasizing the shift toward personalized, patient-centered therapy strategies.

Discover how recent studies shift minimal residual disease testing from a prognostic tool to a key player in managing hematological malignancies.

Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.

Discover groundbreaking advancements in prostate cancer treatment with innovative PROTAC drugs, promising new trials, and enhanced therapy effectiveness.

Navigating the complex landscape of prostate cancer treatment sequencing is crucial for maximizing patient outcomes and survival rates.

Pierre Gholam, MD, observes the improvements in outcomes with lenvatinib seen in recent trials of unresectable hepatocellular carcinoma compared with the original phase 3 REFLECT trial.

Jason S. Starr, DO, discusses the CABINET trial of cabozantinib in pancreatic neuroendocrine tumors.

A new subcutaneous formulation of amivantamab shows high efficacy and improved safety for advanced NSCLC patients, enhancing treatment convenience.

Andrew Jallouk, MD, discusses the surge of approved therapies in lymphoma over the past decade.

Andrew Jallouk, MD, highlights the challenges in lymphoma treatment, including access disparities and the need for personalized therapies for better patient outcomes.

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in patients with lung cancer patients undergoing treatment with amivantamab and lazertinib.

New 5-year data reveals cemiplimab plus chemotherapy significantly enhances survival rates for advanced non-small cell lung cancer patients.

Joseph Jacob, MD, discusses gemcitabine intravesical delivery as a highly effective treatment for high-risk, BCG-unresponsive bladder cancer, achieving an 82% response rate.

Joseph Jacob, MD, discusses the how the recent FDA approval of the gemcitabine intravesical system offers a radically different treatment approach for patients with bladder cancer.

Binod Dhakal, MD, discusses the BOSTON trial of selinexor combination therapy in patients with relapsed/refractory multiple myeloma.

Hardeep Phull, MD, explains the impact that telehealth has had for oncologists and patients.

A novel trispecific antibody, JNJ-5322, shows remarkable efficacy in treating multiple myeloma, achieving a 100% response rate in trials.

A panelist discusses how this is an exciting time for pancreatic cancer treatment with the development of RAS inhibitors targeting KRAS mutations (present in approximately 90% of patients with metastatic pancreatic cancer, including G12D, G12V, and G12C variants), which have shown impressive response rates in later-line settings and are being evaluated in frontline trials, before concluding the Targeted Oncology discussion on the metastatic pancreatic adenocarcinoma treatment landscape.

A recent trial reveals cemiplimab significantly reduces recurrence in high-risk cutaneous squamous cell carcinoma, setting a new standard for adjuvant treatment.

Panelist discusses how NALIRIFOX (liposomal irinotecan, 5-fluorouracil, leucovorin, oxaliplatin) represents a reasonable treatment option for patients with excellent performance status and locally advanced pancreatic adenocarcinoma, requiring close monitoring and proactive toxicity management to maximize outcomes.

Panelist discusses how post hoc analyses of the NAPOLI-3 trial revealed that dose reductions for toxicity management do not adversely affect overall survival and that UGT1A1 mutations do not significantly impact treatment tolerability with nanoliposomal irinotecan.

Experts explore the potential of invasive disease-free survival as a key metric in breast cancer trials, aiming to accelerate treatment approvals.

Christina Poh, MD, explores tafasitamab's universal benefits for follicular lymphoma treatment, highlighting its practical adoption and safety for all patients.

George Mulligan, PhD, highlights the importance of clinical trials and innovative research in advancing myeloma treatment and pursuing potential cures.

Bradley A. McGregor, MD, discusses the challenges shared by oncologists who treat renal cell carcinoma.

George Mulligan, PhD, explores the impact of linvoseltamab's FDA approval on multiple myeloma treatment, highlighting innovative bispecific antibodies and patient-centered strategies.

Dr Patrick Wen discusses the FDA approval of dordaviprone, highlighting its potential to improve outcomes for patients with challenging brain tumors.

A panelist discusses how proactive adverse event management is crucial for patients with metastatic pancreatic cancer, including using every-2-week scheduling and primary granulocyte colony-stimulating factor (G-CSF) support to reduce myelosuppression, providing extensive patient counseling about diet, hydration, and early antidiarrheal use for liposomal irinotecan-related diarrhea, and closely monitoring for cumulative neuropathy with consideration of oxaliplatin discontinuation by 3 to 4 months if responding to prevent limitations on future therapy options.

A panelist discusses how treating metastatic pancreatic cancer requires a multidisciplinary approach with early palliative care and dietitian involvement, emphasizing that for patients with good performance status, 3-drug regimens like NALIRIFOX or modified FOLFIRINOX can provide clinical responses and quality-of-life improvements even in high disease burden cases, whereas frail patients benefit from gemcitabine plus nab-paclitaxel administered every 2 weeks, and notes that age alone should not exclude patients from 3-drug regimens as the NAPOLI-3 trial included patients aged up to 85 years.